Clinical Laserthermia Systems (CLS) Q3 2024 earnings summary

Executive summary

• Net sales for the first nine months rose to SEK 14.2 million, up over 270% year-over-year, driven by ClearPoint Prism neurosurgery system adoption.

• Loss after financial items improved to SEK -39.1 million from SEK -55.2 million year-over-year, reflecting cost reductions and business focus.

• Strategic shift to focus exclusively on neurosurgery, exiting unprofitable urology operations for higher margins and efficiency.

• Board changes: Peter Max appointed Chairman, with new and re-elected members bringing international life science expertise.

Financial highlights

• Q3 net sales reached SEK 5.4 million, up more than 170% compared to Q3 2023.

• Q3 loss after financial items improved to SEK -13.0 million from SEK -17.2 million year-over-year.

• Basic and diluted EPS for Q3 was SEK -0.98, compared to SEK -3.3 in Q3 2023.

• Equity ratio remained strong at 85% at September 30, 2024.

• Cash and cash equivalents at period end were SEK 15.6 million.

Outlook and guidance

• Targeting positive EBITDA in 2026, with operating expenditure reductions of at least 30% in 2025 over 2024.

• Anticipates gross margins of 60% by end of 2026, with recurring disposables sales margins of 80%+.

• All resources dedicated to accelerating neurosurgery commercialization via ClearPoint Neuro partnership.